Efficacy and safety of tazemetostat, an EZH2 inhibitor, in Chinese patients with relapsed/refractory follicular lymphoma: a multicentre, single-arm, phase 2 study.

ABSTRACT:

Background

Tazemetostat, the first enhancer of zeste homolog 2 (EZH2) inhibitor approved by the U.S. Food and Drug Administration, has shown efficacy in a global population with relapsed or refractory (R/R) follicular lymphoma (FL). This phase 2 study was primarily designed as a registration-intent bridging trial of tazemetostat in Chinese patients with EZH2-mutant (EZH2 ^mut) R/R FL; the study also included evaluation in the EZH2 wild-type (EZH2 ^wt) population.

Methods

This multicentre, single-arm, phase 2 study was conducted at 19 sites in China. Eligible patients (aged ≥18 years) with histologically confirmed grade 1-3a FL were categorised by EZH2 status: mutant (EZH2 ^mut, bridging cohort) and wild-

SUBMITTER: Cao J 

PROVIDER: S-EPMC12391435 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature